Growth hormone corrects vascular dysfunction in patients with chronic heart failure.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The goal of this study was to test the hypothesis that growth hormone (GH) administration to patients with chronic heart failure (CHF) corrects their vascular dysfunction.

Why It Was Studied

Endothelial dysfunction is a prominent feature of CHF.

Recent evidence indicates that GH plays a role in vascular reactivity.

Who Took Part

The abstract describes 16 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

The researchers measured forearm blood flow (FBF) by strain-gauge plethysmography during intrabrachial, graded infusion of acetylcholine (ACh) and sodium nitroprusside (NP).

The researchers also measured the forearm balance of nitrite and cyclic guanosine monophosphate (cGMP) before and during ACh infusion.

Maximal oxygen uptake (VO2max) was measured by breath-to-breath respiratory gas analysis.

What Was Measured

Topics PubMed links to this paper include Acetylcholine, Endothelium, Vascular, Forearm, Heart Failure, Human Growth Hormone, Insulin-Like Growth Factor I and Regional Blood Flow.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 16 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2002 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.